menu search

IMNM / Immunome to Present at 13th Annual World ADC London Conference

Immunome to Present at 13th Annual World ADC London Conference
EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop antibody therapeutics to improve patient care, today announced that Matthew Robinson, Ph.D., Chief Technology Officer, will present at the 13th Annual World ADC London conference, taking place from March 13-16, 2023. Read More
Posted: Mar 9 2023, 08:45
Author Name: Business Wire
Views: 102278

IMNM News  

Immunome: The Morphimmune Merger And The Pipeline

By Seeking Alpha
September 28, 2023

Immunome: The Morphimmune Merger And The Pipeline

IMNM is set to merge with Morphimmune, pending a shareholder vote on September 29. The current CEO of Morphimmune, Clay Siegall, would become the new more_horizontal

Immunome (IMNM) Surges on Merger Agreement With Morphimmune

By Zacks Investment Research
June 30, 2023

Immunome (IMNM) Surges on Merger Agreement With Morphimmune

Immunome's (IMNM) shares rise following its announcement to merge with Morphimmune. The synergy will help strengthen the development of oncology thera more_horizontal

Recent Price Trend in Immunome, Inc. (IMNM) is Your Friend, Here's Why

By Zacks Investment Research
March 22, 2023

Recent Price Trend in Immunome, Inc. (IMNM) is Your Friend, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Immunome, Inc. (IMNM) could be a great choice. It is one of t more_horizontal

Immunome to Present at 13th Annual World ADC London Conference

By Business Wire
March 9, 2023

Immunome to Present at 13th Annual World ADC London Conference

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and more_horizontal

Immunome: Clinical Data With A COVID Therapeutic And The AbbVie Collaboration

By Seeking Alpha
January 31, 2023

Immunome: Clinical Data With A COVID Therapeutic And The AbbVie Collaboration

Topline data from Immunome's phase 1b trial of its COVID antibody drug, IMM-BCP-01, have led the company to look for a partner for further development more_horizontal

AbbVie Briefly Breaks Out After Tapping Immunome In $30 Million Cancer Deal

By Investors Business Daily
January 6, 2023

AbbVie Briefly Breaks Out After Tapping Immunome In $30 Million Cancer Deal

AbbVie stock briefly broke out Friday after the company signed a $30 million deal with small biotech Immunome in antibody development. The post AbbVie more_horizontal

Immunome Shares Rise After Publishing Positive COVID-19 Antibody Cocktail Data

By Benzinga
May 19, 2022

Immunome Shares Rise After Publishing Positive COVID-19 Antibody Cocktail Data

Immunome Inc (NASDAQ: IMNM) shares are trading higher after it published data demonstrating that its COVID-19 antibody cocktail, IMM-BCP-01, potentl more_horizontal

Immunome Shares Seesaw After COVID-19 Antibody Cocktail Works Against Live Omicron Virus

By Benzinga
February 8, 2022

Immunome Shares Seesaw After COVID-19 Antibody Cocktail Works Against Live Omicron Virus

Immunome Inc IMNM shares rose before falling after reporting results from testing its experimental three-antibody cocktail against live versions of more_horizontal


Search within

Pages Search Results: